Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Drug Resistance

  Free Subscription

Articles published in Antivir Ther

Retrieve available abstracts of 29 articles:
HTML format
Text format

Single Articles

    January 2017
  1. SIMONETTI FR, Cattaneo D, Zanchetta N, Giacomet V, et al
    Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for TDM.
    Antivir Ther. 2017 Jan 4. doi: 10.3851/IMP3122.
    PubMed     Text format     Abstract available

  2. DONG H, Zhou B, Kang H, Jin W, et al
    Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients.
    Antivir Ther. 2017;22:43-51.
    PubMed     Text format     Abstract available

    November 2016
  3. GILL VC, Lynch T, Ramazani S, Krentz HB, et al
    Reporting on the prevalence of antiretroviral drug resistance in a regional HIV population over 20 years: a word of caution.
    Antivir Ther. 2016 Nov 2. doi: 10.3851/IMP3105.
    PubMed     Text format     Abstract available

    September 2016
  4. CAPETTI AF, Orofino G, Sterrantino G, Cossu MV, et al
    Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
    Antivir Ther. 2016 Sep 23. doi: 10.3851/IMP3095.
    PubMed     Text format     Abstract available

    May 2016
  5. ARCHAMPONG TN, Boyce CL, Lartey M, Sagoe KW, et al
    HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
    Antivir Ther. 2016 May 11. doi: 10.3851/IMP3055.
    PubMed     Text format     Abstract available

    March 2016
  6. MIKULA JM, Manion MM, Maldarelli F, Suarez LM, et al
    Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir DF-associated renal tubulopathy.
    Antivir Ther. 2016 Mar 8. doi: 10.3851/IMP3040.
    PubMed     Text format     Abstract available

    January 2016
  7. SILVEIRA FP, Abdel-Massih R, Bogdanovich T, Pakstis DL, et al
    Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181, a host-directed antiviral.
    Antivir Ther. 2016;21:71-4.
    PubMed     Text format     Abstract available

  8. KINUGASA H, Ikeda F, Takaguchi K, Mori C, et al
    Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
    Antivir Ther. 2016;21:37-44.
    PubMed     Text format     Abstract available

    November 2015
  9. TAMBUYZER L, Thys K, Hoogstoel A, Nijs S, et al
    Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
    Antivir Ther. 2015 Nov 13. doi: 10.3851/IMP3011.
    PubMed     Text format     Abstract available

  10. NDAHIMANA JD, Riedel DJ, Muhayimpundu R, Nsanzimana S, et al
    HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda.
    Antivir Ther. 2015 Nov 12. doi: 10.3851/IMP3005.
    PubMed     Text format     Abstract available

    August 2015
  11. FLORIS-MOORE MA, Mollan K, Wilkin AM, Johnson MA, et al
    Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
    Antivir Ther. 2015 Aug 11. doi: 10.3851/IMP2982.
    PubMed     Text format     Abstract available

    June 2015
  12. LIU Y, Xin S, Ye X, Chen R, et al
    Increased occurrence of mutant rtI233V of HBV in patients with adefovir therapy.
    Antivir Ther. 2015 Jun 16. doi: 10.3851/IMP2971.
    PubMed     Text format     Abstract available

    April 2015
  13. HUHN GD, Sigman A, Livak B
    Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
    Antivir Ther. 2015 Apr 17. doi: 10.3851/IMP2962.
    PubMed     Text format     Abstract available

    February 2015
  14. WAGNER S, Kurz M, Klimkait T
    Algorithm evolution for drug resistance prediction: comparison of systems for HIV-1 genotyping.
    Antivir Ther. 2015 Feb 24. doi: 10.3851/IMP2947.
    PubMed     Text format     Abstract available

    January 2015
  15. GEIPEL A, Seiz PL, Niekamp H, Neumann-Fraune M, et al
    Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.
    Antivir Ther. 2015 Jan 5. doi: 10.3851/IMP2928.
    PubMed     Text format     Abstract available

  16. GRUND S, Gkioule C, Termos T, Pfeifer N, et al
    Primarily oseltamivir-resistant influenza A (H1N1pdm09) virus evolving into a multidrug-resistant virus carrying H275Y and I223R neuraminidase substitutions.
    Antivir Ther. 2015;20:97-100.
    PubMed     Text format     Abstract available

  17. MCCORMICK AL, Wang L, Garcia-Diaz A, Macartney MJ, et al
    Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.
    Antivir Ther. 2015;20:81-5.
    PubMed     Text format     Abstract available

  18. BENSCHOP KS, van der Avoort HG, Duizer E, Koopmans MP, et al
    Antivirals against enteroviruses: a critical review from a public-health perspective.
    Antivir Ther. 2015;20:121-30.
    PubMed     Text format     Abstract available

  19. DEBACK C, Burrel S, Varnous S, Carcelain G, et al
    Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.
    Antivir Ther. 2015;20:249-54.
    PubMed     Text format     Abstract available

  20. APPLEGATE TL, Gaudieri S, Plauzolles A, Chopra A, et al
    Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.
    Antivir Ther. 2015;20:199-208.
    PubMed     Text format     Abstract available

  21. LISBOA-NETO G, Noble CF, Pinho JR, Malta FM, et al
    Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
    Antivir Ther. 2015;20:281-7.
    PubMed     Text format     Abstract available

  22. MCCORMICK AL, Moynihan L, Macartney MJ, Garcia-Diaz A, et al
    Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients.
    Antivir Ther. 2015;20:361-3.
    PubMed     Text format    

  23. ALOIA AL, Eyre NS, Black S, Bent SJ, et al
    Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Antivir Ther. 2015;20:271-80.
    PubMed     Text format     Abstract available

    October 2014
  24. WHITE KL, Kulkarni R, McColl DJ, Rhee MS, et al
    Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
    Antivir Ther. 2014 Oct 16. doi: 10.3851/IMP2885.
    PubMed     Text format     Abstract available

  25. AKIL B, Blick G, Hagins DP, Ramgopal MN, et al
    Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
    Antivir Ther. 2014 Oct 16. doi: 10.3851/IMP2878.
    PubMed     Text format     Abstract available

    July 2014
  26. LI X, Liu Y, Zhao P, Wang Y, et al
    Investigation into drug-resistant mutations of HBV from 845 nucleos(t)ide analogue-naive Chinese patients with chronic HBV infection.
    Antivir Ther. 2014 Jul 3. doi: 10.3851/IMP2813.
    PubMed     Text format     Abstract available

    June 2014
  27. BLANCO JL, Gonzalez-Cordon A, Llibre JM, Calvo M, et al
    Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir.
    Antivir Ther. 2014 Jun 25. doi: 10.3851/IMP2812.
    PubMed     Text format     Abstract available

    May 2014
  28. STEKLER JD, McKernan J, Milne R, Tapia KA, et al
    Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.
    Antivir Ther. 2014 May 15. doi: 10.3851/IMP2780.
    PubMed     Text format     Abstract available

    April 2014
  29. VARDHANABHUTI S, Taiwo B, Kuritzkes DR, Eron JJ Jr, et al
    Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viremia.
    Antivir Ther. 2014 Apr 4. doi: 10.3851/IMP2772.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.